Madhur Roberts, MD
Interventional Cardiology · New Orleans, LANPI 1114275997
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,418 of the $5,040 with a category attached, or 87.7%. It is spread thinly across 26 manufacturers, the largest accounting for just 21.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,588 and has fallen 71.1% since, to $459 in 2025. That places this record below the midpoint for interventional cardiology clinicians in LA, where the typical reported total is $9,970.
Across 104 payments — averaging $48.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1K
- Shockwave Medical, Inc$1K
- Abiomed$496
- Abbott$482
- Biotronik Inc.$481
- Boston Scientific$354
- plus $1K from 20 others
Across 6 payments — averaging $3744.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Shockwave Medical, Inc$22K
What the payments were for
- Travel & lodging$62212%
- Food & beverage$4,41888%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 16 | $1,102 |
| Shockwave Medical, Inc | 14 | $1,072 |
| Abiomed | 7 | $496 |
| Abbott | 8 | $482 |
| Biotronik Inc. | 5 | $481 |
| Boston Scientific | 11 | $354 |
| Siemens Medical Solutions USA, Inc. | 2 | $201 |
| Johnson & Johnson | 7 | $127 |
| Amgen | 2 | $120 |
| Philips North America LLC | 3 | $65 |
| Elutia, Inc. | 2 | $57 |
| Regeneron Healthcare Solutions, Inc. | 3 | $52 |
| Boehringer Ingelheim | 3 | $51 |
| Terumo Medical Corporation | 2 | $49 |
| E.r. Squibb & Sons, L.L.C. | 3 | $47 |
| AstraZeneca | 3 | $44 |
| Novartis | 2 | $39 |
| Pfizer | 2 | $38 |
| Inari Medical, Inc. | 2 | $34 |
| Biosense Webster, Inc. | 1 | $26 |
| W. L. Gore & Associates, Inc. | 1 | $26 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $20 |
| Cardiva Medical, Inc. | 1 | $19 |
| United Therapeutics Corporation | 1 | $17 |
| Portola Pharmaceuticals, LLC | 1 | $11 |
| Bayer | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VenaSeal$482
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$420
- Impella$332
- Orsiro Mission$321
- COREVALVE EVOLUT R$139
- AVVIGO Guidance System$134
- OPTIS$125
- CorPath Imaging System$112
- PK Papyrus$104
- Pulsar$104
- PRO-Kinetic Energy$104
- Orsiro$104
- Astron; Pulsar; AstronPulsar$104
- Repatha$102
- CARDIOMEMS$100
How this compares
$5,040 in reported general payments places this provider in the 30th percentile of 171 interventional cardiology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrilintaTicagrelor | 19 | $16,464 |
| EliquisApixaban | 11 | $8,850 |
| Atorvastatin Calcium | 13 | $118 |
| Metoprolol Succinate | 13 | $41 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBrilinta | $44 | $16,46419 claims |
| PfizerEliquis | $38 | $8,85011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 171 interventional cardiology providers in Louisiana.
Other interventional cardiology in New Orleans
- Rajan PatelNew Orleans$517K
- James JenkinsNew Orleans$235K
- Stephen RameeNew Orleans$56K
- Jose Tafur SotoNew Orleans$44K
- Jose WileyNew Orleans$34K
- Zach RozenbaumNew Orleans$18K
- Aashish GuptaNew Orleans$18K
- Craig WalkerHouma$5M
- Denzil MoraesBaton Rouge$901K
- Ankur LodhaLafayette$640K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.